Stay updated with breaking news from Patrick Barth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from F. Hoffmann-La Roche Ltd, FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and are now in line with the prior year for
Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.Collaboration with PathAI
Investegate announcements from F. Hoffmann-La Roche Ltd, US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival